Theolytics has named Matilde Saggese as its new Chief Medical Officer, as the Oxford-based biotech company accelerates ...

Symeres has appointed Gabriella Gentile as Chief Operating Officer, strengthening its executive team as the company pursues ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted the vital role of advanced therapies in supporting the UK Government’s goal of becoming a top three global life sciences economy by ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast ...

Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of ...

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...

Donatello Crocetta, Chief Medical Officer at UCB, said: “These results for bimekizumab show meaningful improvements in inflammatory lesions and skin pain to three years, and offer a valuable ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal ...

Evotec SE has announced a $25m milestone payment from Bristol Myers Squibb, recognising scientific progress made within their ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...